| Name | Title | Contact Details |
|---|---|---|
Mike Willingham |
Corporate Director of Information Technology | Profile |
Founded in 2019, Advanced Solution is proudly Christian and Veteran owned. Advanced Solution is one of the fastest growing medical solutions distribution networks in the United States, serving US Veterans Affairs Health Systems, Hospital Outpatient Departments, Operating Rooms and Privately Owned Specialty Clinics throughout North America. Advanced Solution originated in Central, Pennsylvania as a solutions-oriented company. Our Executive Leadership team has partnered with multiple market leading Tissue Banks and Master Distribution Networks. When a physician partners with Advanced Solution, they gain access to a network of over 30 advanced treatment modalities. — COMPASSION. INNOVATION. TRUST. —
Lancaster County Motors is an automotive sales and service company based in East Petersburg, Pennsylvania. Our dealerships include Lancaster County Motors Subaru, Lancaster Hyundai, Lancaster County Kia, Mercedes-Benz of Lancaster, Providence Autos, and LCM Used Cars.
The Familie specializes in talent representation across sports and music.
At Zevtron, we develop solutions to help forward thinking organizations more efficiently and responsibly facilitate the use of electricity for transportation fuel. We are committed to provide our customers with reliable and economically viable plug-in electric vehicle charging solutions to help accelerate the installation of plug-in vehicle infrastructure.
IMUNON is a fully integrated, clinical stage biotechnology company focused on advancing a portfolio of innovative treatments that harness the bodys natural mechanisms to generate safe, effective, and durable responses across a broad array of human diseases. IMUNON has two platform technologies: Our TheraPlas® platform for the development of immunotherapies and other anti-cancer nucleic acid-based therapies and our PLACCINE platform for the development of nucleic acid vaccines for infectious diseases and cancer. The Companys lead clinical program, GEN-1, is a DNA-based immunotherapy for the localized treatment of advanced ovarian cancer currently in Phase II development. GEN-1 works by instructing the body to produce safe and durable levels of powerful cancer fighting molecules, such as interleukin-12 (IL-12) and interferon gamma (IFN-γ), at the tumor site. In addition, we are conducting pre-clinical proof-of-concept studies on a nucleic acid vaccine candidate targeting SARS-CoV-2 virus in order to validate our PLACCINE platform. IMUNONs platform technologies are based on the delivery of nucleic acids with novel synthetic delivery systems that are independent of viral vectors or devices. We will continue to leverage these platforms and to advance the technological frontier of plasmid DNA to better serve patients with difficult to treat conditions.